Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: | Recruiting |
---|---|
Conditions: | Other Indications, Blood Cancer |
Therapuetic Areas: | Oncology, Other |
Healthy: | No |
Age Range: | 30 - 70 |
Updated: | 4/4/2019 |
Start Date: | December 23, 2013 |
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how
well it works compared to induction chemotherapy alone in treating patients with newly
diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase
(ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal
antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread It is not yet known whether
combination chemotherapy is more effective with or without blinatumomab in treating newly
diagnosed acute lymphoblastic leukemia.
well it works compared to induction chemotherapy alone in treating patients with newly
diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase
(ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal
antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread It is not yet known whether
combination chemotherapy is more effective with or without blinatumomab in treating newly
diagnosed acute lymphoblastic leukemia.
PRIMARY OBJECTIVES:
I. To compare the overall survival (OS) of blinatumomab in conjunction with chemotherapy to
chemotherapy alone in patients with BCR-ABL-negative B cell precursor acute lymphoblastic
leukemia (ALL) who are minimal residual disease (MRD) positive after induction and
intensification chemotherapy, based on multiparameter flow cytometric (MFC) assessment of
residual blasts.
SECONDARY OBJECTIVES:
I. To compare the relapse-free survival (RFS) of blinatumomab in conjunction with
chemotherapy to chemotherapy alone in MRD positive patients, MRD negative patients and
overall population after induction and intensification chemotherapy.
II. To compare the OS and RFS of those patients who are MRD+ at step 3 randomization/
registration and then convert to MRD- after 2 cycles of blinatumomab to those patients who
are MRD- at randomization and remain MRD- after 2 cycles of blinatumomab or consolidation
chemotherapy.
III. To assess the toxicities of blinatumomab in this patient population. IV. To assess the
toxicities of the modified E2993 chemotherapy regimen in this patient population.
V. To describe the outcome of patients who proceed to allogeneic blood or marrow transplant
after treatment with or without blinatumomab.
LABORATORY OBJECTIVES:
I. To determine differences in MRD kinetics among patients with the BCR/ABL1-like B-lineage
ALL, and assess the efficacy of blinatumomab in each molecular subgroup.
II. To evaluate the incidence of anti-blinatumomab antibody formation.
OUTLINE:
INDUCTION CHEMOTHERAPY: Patients receive cytarabine intrathecally (IT) on day 1; daunorubicin
hydrochloride intravenously (IV) over 10-15 minutes on days 1, 8, 15, and 22; vincristine
sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) daily on days 1-7 (and 15-21
for patients age < 55 years only); methotrexate IT on day 14; pegaspargase intramuscularly
(IM) or IV on day 18 (patients age =< 55 years); and CD20 positive patients may optionally
receive rituximab IV on day 8 and 15. Beginning on day 29, patients with absolute neutrophil
count (ANC) >= 0.75 x 10^9/L and platelets > 75 x 10^9/L (patients with delayed hematologic
recovery) (patients with residual disease that is delaying count begin treatment immediately)
receive cyclophosphamide IV over 30 minutes on days 1 and 29, cytarabine IV over 30 minutes
or subcutaneously (SC) on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14,
29-42, pegaspargase IM or IV on day 15 (patients age < 55 years), patients receiving
treatment for central nervous system (CNS) 2 or 3 leukemia in course 1 receive methotrexate
IT on days 1, 8, 15, and 22, and CD20 positive patients may optionally receive rituximab IV
on days 8 and 15.
INTENSIFICATION THERAPY: Beginning 4 weeks after the completion of course 2 of induction
therapy, patients receive intensification therapy comprising high-dose methotrexate IV over 2
hours on days 1 and 8, and pegaspargase IM or IV on day 9.
Patients are then randomized to 1 of 2 treatment arms.
Patients randomized to the blinatumomab group receive blinatumomab IV continuously on days
1-28. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or
unacceptable toxicity. Patients may then undergo allogeneic stem cell transplant (SCT) or
proceed to consolidation therapy per investigator discretion.
CONSOLIDATION THERAPY: Beginning after the second course of blinatumomab (patients randomized
to the blinatumomab group) or after intensification therapy (patients not randomized to
blinatumomab), patients receive cytarabine IV over 30 minutes or SC on days 1-5, etoposide IV
over 1 hour on days 1-5, methotrexate IT on day 1, and pegaspargase IM or IV on day 5, and
CD20 positive patients may optionally receive rituximab IV on day 5. Beginning 4 weeks from
day 1 of course 1, patients receive cytarabine, etoposide, methotrexate, and CD20 positive
patients may receive rituximab as in course 1. Beginning 4 weeks from day 1 of course 2,
patients receive daunorubicin hydrochloride IV over 10-15 minutes on day 1, 8, 15, and 22;
vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone PO daily on days 1-7 (and
15-21 for patients age < 55 years); methotrexate IT on day 2; cyclophosphamide PO or IV over
30 minutes on day 29; cytarabine IV over 30 minutes or SC on days 30-33 and 37-40;
mercaptopurine PO on days 29-42 and CD20 positive patients may receive rituximab on day 8.
Beginning 8 weeks from day 1 of course 3, patients receive cytarabine, etoposide,
methotrexate, and CD20 positive patients may optionally receive rituximab as in course 1.
Patients randomized to blinatumomab repeat course 4 and then receive blinatumomab IV
continuously on days 1-28.
MAINTENANCE THERAPY: Within 12 weeks after beginning last course of consolidation therapy,
patients receive mercaptopurine PO daily, methotrexate PO or IV over 6 hours once weekly for
2.5 years, vincristine sulfate IV on day 1 every 3 months, prednisone PO on days 1-5 every 3
months, and methotrexate IT on day 1 every 3 months. Treatment continues for up to 2.5 years
in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then every 12 months for 5 years.
I. To compare the overall survival (OS) of blinatumomab in conjunction with chemotherapy to
chemotherapy alone in patients with BCR-ABL-negative B cell precursor acute lymphoblastic
leukemia (ALL) who are minimal residual disease (MRD) positive after induction and
intensification chemotherapy, based on multiparameter flow cytometric (MFC) assessment of
residual blasts.
SECONDARY OBJECTIVES:
I. To compare the relapse-free survival (RFS) of blinatumomab in conjunction with
chemotherapy to chemotherapy alone in MRD positive patients, MRD negative patients and
overall population after induction and intensification chemotherapy.
II. To compare the OS and RFS of those patients who are MRD+ at step 3 randomization/
registration and then convert to MRD- after 2 cycles of blinatumomab to those patients who
are MRD- at randomization and remain MRD- after 2 cycles of blinatumomab or consolidation
chemotherapy.
III. To assess the toxicities of blinatumomab in this patient population. IV. To assess the
toxicities of the modified E2993 chemotherapy regimen in this patient population.
V. To describe the outcome of patients who proceed to allogeneic blood or marrow transplant
after treatment with or without blinatumomab.
LABORATORY OBJECTIVES:
I. To determine differences in MRD kinetics among patients with the BCR/ABL1-like B-lineage
ALL, and assess the efficacy of blinatumomab in each molecular subgroup.
II. To evaluate the incidence of anti-blinatumomab antibody formation.
OUTLINE:
INDUCTION CHEMOTHERAPY: Patients receive cytarabine intrathecally (IT) on day 1; daunorubicin
hydrochloride intravenously (IV) over 10-15 minutes on days 1, 8, 15, and 22; vincristine
sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) daily on days 1-7 (and 15-21
for patients age < 55 years only); methotrexate IT on day 14; pegaspargase intramuscularly
(IM) or IV on day 18 (patients age =< 55 years); and CD20 positive patients may optionally
receive rituximab IV on day 8 and 15. Beginning on day 29, patients with absolute neutrophil
count (ANC) >= 0.75 x 10^9/L and platelets > 75 x 10^9/L (patients with delayed hematologic
recovery) (patients with residual disease that is delaying count begin treatment immediately)
receive cyclophosphamide IV over 30 minutes on days 1 and 29, cytarabine IV over 30 minutes
or subcutaneously (SC) on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14,
29-42, pegaspargase IM or IV on day 15 (patients age < 55 years), patients receiving
treatment for central nervous system (CNS) 2 or 3 leukemia in course 1 receive methotrexate
IT on days 1, 8, 15, and 22, and CD20 positive patients may optionally receive rituximab IV
on days 8 and 15.
INTENSIFICATION THERAPY: Beginning 4 weeks after the completion of course 2 of induction
therapy, patients receive intensification therapy comprising high-dose methotrexate IV over 2
hours on days 1 and 8, and pegaspargase IM or IV on day 9.
Patients are then randomized to 1 of 2 treatment arms.
Patients randomized to the blinatumomab group receive blinatumomab IV continuously on days
1-28. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or
unacceptable toxicity. Patients may then undergo allogeneic stem cell transplant (SCT) or
proceed to consolidation therapy per investigator discretion.
CONSOLIDATION THERAPY: Beginning after the second course of blinatumomab (patients randomized
to the blinatumomab group) or after intensification therapy (patients not randomized to
blinatumomab), patients receive cytarabine IV over 30 minutes or SC on days 1-5, etoposide IV
over 1 hour on days 1-5, methotrexate IT on day 1, and pegaspargase IM or IV on day 5, and
CD20 positive patients may optionally receive rituximab IV on day 5. Beginning 4 weeks from
day 1 of course 1, patients receive cytarabine, etoposide, methotrexate, and CD20 positive
patients may receive rituximab as in course 1. Beginning 4 weeks from day 1 of course 2,
patients receive daunorubicin hydrochloride IV over 10-15 minutes on day 1, 8, 15, and 22;
vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone PO daily on days 1-7 (and
15-21 for patients age < 55 years); methotrexate IT on day 2; cyclophosphamide PO or IV over
30 minutes on day 29; cytarabine IV over 30 minutes or SC on days 30-33 and 37-40;
mercaptopurine PO on days 29-42 and CD20 positive patients may receive rituximab on day 8.
Beginning 8 weeks from day 1 of course 3, patients receive cytarabine, etoposide,
methotrexate, and CD20 positive patients may optionally receive rituximab as in course 1.
Patients randomized to blinatumomab repeat course 4 and then receive blinatumomab IV
continuously on days 1-28.
MAINTENANCE THERAPY: Within 12 weeks after beginning last course of consolidation therapy,
patients receive mercaptopurine PO daily, methotrexate PO or IV over 6 hours once weekly for
2.5 years, vincristine sulfate IV on day 1 every 3 months, prednisone PO on days 1-5 every 3
months, and methotrexate IT on day 1 every 3 months. Treatment continues for up to 2.5 years
in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then every 12 months for 5 years.
Inclusion Criteria:
- PRE-REGISTRATION
- Diagnostic bone marrow and peripheral blood specimens must be submitted for
immunophenotyping and selected molecular testing, and the establishment of BCR/ABL
status; testing will be performed by the Eastern Cooperative Oncology Group
(ECOG)-American College of Radiation Imaging Network (ACRIN) Leukemia Translational
Research Laboratory (LTRL) and reported to the institution
- NOTE: IT IS ESSENTIAL THAT A SAMPLE CONTAINING SUFFICIENT BLAST CELLS BE
SUBMITTED TO THE ECOG-ACRIN LTRL AT BASELINE SO THAT SUBSEQUENT BONE MARROW
ASSESSMENTS OF MRD CAN BE DONE; IN ADDITION TO ALLOWING THE LTRL TO CONFIRM
ELIGIBILITY BASED ON BLAST CELL IMMUNOPHENOTYPE AND BCR/ABL STATUS, IT IS ALSO
IMPERATIVE THAT AN ADEQUATE NUMBER OF BLASTS BE BANKED FOR ANALYSIS BY DRS
MULLIGHAN/WILLMAN. WITHOUT ADEQUATE BASELINE SAMPLES, PATIENTS WILL NOT BE ABLE
TO BE TREATED AND RANDOMIZED ON THIS PROTOCOL; IF A BONE MARROW ASPIRATE IS NOT
AVAILABLE FOR LTRL SUBMISSION AT BASELINE, IT IS IMPERATIVE THAT DR PAIETTA FROM
THE LTRL IS CALLED TO DISCUSS THE PERIPHERAL BLOOD WBC AND BLAST COUNT BEFORE
BLOOD ONLY IS SUBMITTED
- NOTE: Hydroxyurea can be given for up to 5 days prior to initiation of protocol
therapy for control of leukocyte count and/or other symptoms or signs;
corticosteroids can be given after pre-registration to the protocol and
submission of baseline marrow and blood samples for control of leukocyte count
and/or other symptoms or signs prior to initiation of protocol therapy if needed;
if corticosteroids are given prior to pre-registration, contact the study chair
as the patient may still be eligible to participate
- INDUCTION ELIGIBILITY CRITERIA-STEP 1
- New diagnosis of B lineage ALL must be made upon bone marrow or peripheral blood
immunophenotyping; cases with myeloid antigen expression, but unequivocal lymphoid
immunophenotype, are eligible
- Mature B ALL (Burkitt's-like leukemia) is excluded from enrollment in this trial;
pre-study bone marrow biopsy and aspirate must be completed =< 1 week prior to
registration
- Negativity for the Philadelphia chromosome must be established by conventional
cytogenetics, fluorescence in situ hybridization (FISH) and/or polymerase chain
reaction (PCR); patients who are negative for the Philadelphia chromosome by
conventional cytogenetics must have FISH or PCR performed for BCR/ABL to exclude
occult translocations
- Cytogenetic analysis must be performed from diagnostic bone marrow (preferred) or if
adequate number of circulating blasts from peripheral blood; FISH testing for common
B-lineage ALL abnormalities including t(9;22) (BCR/ABL1), t(12;21) (ETS-variant gene 6
[ETV6]/runt-related transcription factor 1 [RUNX1]), t(1;19) (pre-B-cell leukemia
homeobox 1 [PBX1]/transcription factor 3 [TCF3]), +4,+10,+17, (centromeric
[Cen]4/Cen10/Cen17), t(11q23;var), (myeloid/lymphoid or mixed lineage leukemia [MLL]),
deletion (del)(9p) (cyclin-dependent kinase inhibitor 2A [CDKN2A]/Cen9), and t(14;var)
(immunoglobulin heavy chain [IGH] is encouraged); if there are few or no circulating
blasts and an adequate marrow sample cannot be obtained for cytogenetic analysis, the
patient may still enroll on the trial
- Patient must not have a concurrent active malignancy for which they are receiving
treatment
- Serum direct bilirubin < 2 mg/dl or serum total bilirubin =< 3 (obtained =< 48 hours
prior to registration); NOTE: the above stipulation for normal hepatic function does
not apply if liver dysfunction is due to leukemia infiltration
- Serum creatinine < 2 mg/dl (obtained =< 48 hours prior to registration); NOTE: the
above stipulation for normal hepatic function does not apply if liver dysfunction is
due to leukemia infiltration
- Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during
induction therapy phase or a written explanation for not undergoing HLA typing on the
flow sheet
- Patient must not have intercurrent organ damage or medical problems that will
jeopardize the outcome of therapy (i.e., psychiatric disorder, drug abuse, pregnancy)
- Patients with known human immunodeficiency virus (HIV) infection are eligible if they
meet all of the following criteria:
- No history of acquired immune deficiency syndrome (AIDS)-related complications
other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of
combination antiretroviral therapy; on study CD4+ T-cell count may not be
informative due to leukemia and should not be used as an exclusion criterion if
low
- Patient must be healthy on the basis of HIV disease with high likelihood of near
normal life span were it not for the leukemia
- Patient must have serum HIV viral load of < 200 copies/mm^3
- Patient must be on combination antiretroviral therapy with minimal
pharmacokinetic interactions with study therapy and minimal overlapping clinical
toxicity with protocol therapy
- Patient must not be receiving protease inhibitors or once daily formulations
containing cobicistat, stavudine, or on regimens containing stavudine or
zidovudine
- It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir,
combined with either disoproxil fumarate/emtricitabine or dolutegravir combined
with tenofovir alafenamide/emtricitabine
- Patient must not have an antecedent hematologic disorder
- Patient must have no history of recent myocardial infarction (within three months),
uncontrolled congestive heart failure, or uncontrolled cardiac arrhythmia
- Patient must not have a history or presence of clinically relevant central nervous
system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe
brain injuries, dementia; Parkinson's disease, cerebellar disease, organic brain
syndrome, psychosis, or other significant CNS abnormalities
- Patient must have a normal cardiac ejection fraction by pretreatment multigated
acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration
(resting ejection fraction >= 40% or >= 5% increase with exercise), shortening
fraction by echocardiogram >= 24%, or to within the normal range of values for the
institution
- Patient must not have an active uncontrolled infection
- Women must not be pregnant or breast-feeding and must not become pregnant or
breastfeed during protocol therapy and for at least 3 months after protocol therapy;
woman of childbearing potential must abstain from sexual activity or be willing to use
2 highly effective forms of contraception throughout protocol therapy and for at least
an additional 3 months after the last dose of protocol-specified therapy; all females
of childbearing potential must have a blood test or urine study within 2 weeks prior
to registration to rule out pregnancy; a female of childbearing potential is any
woman, regardless of sexual orientation or whether they have undergone tubal ligation,
who meets the following criteria: has not undergone a hysterectomy or bilateral
oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive
months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Men who have a female partner of childbearing potential must be willing to use 2
highly effective forms of contraception throughout protocol therapy and for at least
an additional 3 months after the last dose of protocol-specified therapy; men who have
a pregnant partner must be willing to use a condom during sexual activity throughout
protocol therapy and for 3 months after the last dose of protocol-specified therapy
- ECOG performance score 0-3
- Patient must have given written informed consent
- POST-INDUCTION THERAPY ELIGIBILITY CRITERIA (PRIOR TO INTENSIFICATION-STEP 2)
- ECOG performance status 0-2
- Patients must have achieved a CR or CRi
- Patients who have achieved a CR or CRi must have maintained peripheral blood evidence
of a CR or CRi
- Patient must be CNS (cerebrospinal fluid [CSF]) negative for leukemia
- Patients must have resolved any serious infectious complications related to induction
- Any significant medical complications related to induction must have resolved
- Serum creatinine =< 2.0 mg/dl (obtained =< 48 hours prior to registration)
- Serum direct bilirubin < 2 mg/dL or serum total bilirubin =< 3 (obtained =< 48 hours
prior to registration)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit
of normal (ULN) (obtained =< 48 hours prior to registration)
- RANDOMIZATION TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3
- Patients must have an ECOG performance status of 0-2
- Patients must have maintained peripheral blood evidence of a remission and must have a
CR or CRi, confirmed on restaging bone marrow (BM) aspirate and biopsy
- Patients must have resolved any serious infectious complications related to therapy
- Any significant medical complications related to therapy must have resolved
- Direct or total bilirubin < 1.5 x ULN (unless related to Gilbert's or Meulengracht's
syndrome); the values must be obtained within 48 hours prior to randomization
- Serum creatinine < 1.5 x ULN; the values must be obtained within 48 hours prior to
randomization
- Bone marrow aspirates must be submitted for centralized minimal residual disease (MRD)
assessment performed by the ECOG-ACRIN Leukemia Translational Research Laboratory
- MRD results will be reported to the submitting institution
- NOTE: FOR MRD ASSESSMENTS, AN ASPIRATE FROM A SEPARATE BONE MARROW ASPIRATION
SITE MUST BE SUBMITTED (THE NEEDLE CAN BE RE-DIRECTED THROUGH THE SAME SKIN
PUNCTURE SITE); ONLY SUBMIT ASPIRATES FROM THE FIRST PULL OF AN ASPIRATION SITE
FOR MRD TESTING; DO NOT SUBMIT SAMPLES FROM THE SECOND OR THIRD PULL OF THE SAME
ASPIRATION SITE
- In B-lineage ALL, MRD levels in peripheral blood or from a dilute marrow
aspiration can be 300% lower, on average, than those in bone marrow at a given
time point; submitting a first pull from a separate aspiration site will ensure
that MRD determinations used in randomization and trial interpretation are
accurate
- NOTE: failure to submit bone marrow aspirates will result in a major
violation at the time of an audit
- CRITERIA FOR ALLOGENEIC TRANSPLANTATION
- A suitable donor must be identified; there are no restrictions on donor type and can
include a matched sibling, a matched or mismatched unrelated donor, a family haplotype
matched donor or a cord blood donor (single or double)
- Patients should meet the eligibility criteria for RANDOMIZATION TO BLINATUMOMAB OR NO
BLINATUMOMAB-STEP 3
- Patients must be considered reliable enough to comply with the medication regimen and
follow-up, and have social support necessary to allow this compliance
- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have an ECOG performance status
of 0-3
- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have maintained peripheral
blood evidence of a remission and must have a CR or CRi, confirmed on restaging BM
aspirate and biopsy
- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have resolved any serious
infectious complications related to therapy
- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Any significant medical complications related
to therapy must have resolved
We found this trial at
480
sites
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
![Beth Israel Deaconess Medical Center](/wp-content/uploads/logos/beth-israel-deaconess-medical-center.jpg)
Principal Investigator: Daniel J. DeAngelo
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
![Roswell Park Cancer Institute](/wp-content/uploads/logos/roswell-park-cancer-institute.jpg)
Principal Investigator: Eunice S. Wang
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
616.391.9000
![Helen DeVos Children's Hospital at Spectrum Health](/wp-content/uploads/logos/helen-devos-children-s-hospital-at-spectrum-health.png)
Principal Investigator: Kathleen J. Yost
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
![West Michigan Cancer Center](/wp-content/uploads/logos/west-michigan-cancer-center.png)
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
![Bronson Methodist Hospital](/wp-content/uploads/logos/bronson-methodist-hospital.png)
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
![University Medical Center of Southern Nevada](/wp-content/uploads/logos/university-medical-center-of-southern-nevada.jpg)
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
![University of Arkansas for Medical Sciences](/wp-content/uploads/logos/university-of-arkansas-for-medical-sciences.jpg)
Principal Investigator: Muthu Veeraputhiran
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
300 Community Drive
Manhasset, New York 11030
Manhasset, New York 11030
(516) 562-0100
![North Shore University Hospital](/wp-content/uploads/logos/north-shore-university-hospital.jpg)
Principal Investigator: Jonathan E. Kolitz
Phone: 516-734-8896
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
![Providence Portland Medical Center](/wp-content/uploads/logos/providence-portland-medical-center.png)
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
![Virginia Commonwealth University Massey Cancer Center](/wp-content/uploads/logos/virginia-commonwealth-university-massey-cancer-center.jpg)
Principal Investigator: Danielle A. Shafer
Phone: 804-628-1939
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
![University of Rochester](/wp-content/uploads/logos/university-of-rochester.png)
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
170 North 1100 East
American Fork, Utah 84003
American Fork, Utah 84003
Principal Investigator: Julie D. Asch
Phone: 801-855-4100
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
Atlanta, Georgia 30342
(404) 851-8000
![Northside Hospital](/wp-content/uploads/logos/northside-hospital.jpg)
Principal Investigator: Henry K. Holland
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Atlanta, Georgia 30322
Principal Investigator: Rebecca B. Klisovic
Phone: 404-778-1868
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
![University of Maryland Greenebaum Cancer Center](/wp-content/uploads/logos/university-of-maryland-greenebaum-cancer-center.jpg)
Principal Investigator: Maria R. Baer
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
![Johns Hopkins University-Sidney Kimmel Cancer Center](/wp-content/uploads/logos/johns-hopkins-university-sidney-kimmel-cancer-center.png)
Principal Investigator: Keith W. Pratz
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
![Eastern Maine Medical Center](/wp-content/uploads/logos/eastern-maine-medical-center.png)
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Basking Ridge, New Jersey 07920
Principal Investigator: Mark B. Geyer
Phone: 212-639-5007
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70809
Principal Investigator: Andrew P. Dalovisio
Phone: 225-761-5346
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70816
Principal Investigator: Andrew P. Dalovisio
Phone: 225-761-5346
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70836
Principal Investigator: Andrew P. Dalovisio
Phone: 504-703-8712
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
![Bronson Battle Creek](/wp-content/uploads/logos/bronson-battle-creek.png)
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2500 Bellevue Medical Center Drive
Bellevue, Nebraska 68123
Bellevue, Nebraska 68123
Principal Investigator: Krishna Gundabolu
Phone: 402-559-6941
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bellevue, Washington 98005
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
8901 Rockville Pike
Bethesda, Maryland 20889
Bethesda, Maryland 20889
(301) 295-4000
![Walter Reed National Military Medical Center](/wp-content/uploads/logos/walter-reed-national-military-medical-center.jpg)
Principal Investigator: Clifton C. Mo
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
![Saint Vincent Healthcare](/wp-content/uploads/logos/saint-vincent-healthcare.png)
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Birmingham, Alabama 35233
Principal Investigator: Nikolaos Papadantonakis
Phone: 205-934-0220
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
![Illinois CancerCare-Bloomington](/wp-content/uploads/logos/illinois-cancercare-bloomington.gif)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
![Saint Luke's Mountain States Tumor Institute](/wp-content/uploads/logos/saint-luke-s-mountain-states-tumor-institute.gif)
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
![Massachusetts General Hospital Cancer Center](/wp-content/uploads/logos/massachusetts-general-hospital-cancer-center.jpg)
Principal Investigator: Daniel J. DeAngelo
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
![Dana-Farber Cancer Institute](/wp-content/uploads/logos/dana-farber-cancer-institute.gif)
Principal Investigator: Daniel J. DeAngelo
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Toledo Clinic Cancer Centers-Bowling Green Our doctors evaluate and make recommendations regarding cancer treatment for...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
![Bozeman Deaconess Hospital](/wp-content/uploads/logos/bozeman-deaconess-hospital.jpg)
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bronx, New York 10461
Principal Investigator: Olga Derman
Phone: 718-904-2730
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bronx, New York 10461
Principal Investigator: Olga Derman
Phone: 718-904-2730
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bronx, New York 10467
Principal Investigator: Olga Derman
Phone: 718-904-2730
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brownstown, Michigan 48183
Principal Investigator: Ding Wang
Phone: 313-916-3721
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
![Saint James Community Hospital and Cancer Treatment Center](/wp-content/uploads/logos/saint-james-community-hospital-and-cancer-treatment-center.png)
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
![Illinois CancerCare - Canton](/wp-content/uploads/logos/illinois-cancercare---canton.jpg)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
![Saint Francis Medical Center](/wp-content/uploads/logos/saint-francis-medical-center.png)
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
![Southeast Cancer Center](/wp-content/uploads/logos/southeast-cancer-center.png)
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
![Illinois CancerCare - Carthage](/wp-content/uploads/logos/illinois-cancercare---carthage.jpg)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Rocky Mountain Oncology Rocky Mountain Oncology Center is a spacious, comfortable, state-of-the-art 19,000 square foot...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1303 North Main Street
Cedar City, Utah 84721
Cedar City, Utah 84721
(435) 868-5680
Principal Investigator: Julie D. Asch
Phone: 435-868-5680
Sandra L. Maxwell Cancer Center The Huntsman-Intermountain Cancer Center at Valley View Medical Center in...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Centralia, Washington 98531
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
505 S Plummer Ave
Chanute, Kansas 66720
Chanute, Kansas 66720
(620) 431-7580
![Cancer Center of Kansas, PA - Chanute](/wp-content/uploads/logos/cancer-center-of-kansas-pa---chanute.jpg)
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Chapel Hill, North Carolina 27599
Principal Investigator: Katarzyna J. Jamieson
Phone: 877-668-0683
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Shira N. Dinner
Phone: 312-695-1301
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
![Univ of Illinois](/wp-content/uploads/logos/univ-of-illinois.jpg)
Principal Investigator: John G. Quigley
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
![University of Chicago Comprehensive Cancer Center](/wp-content/uploads/logos/university-of-chicago-comprehensive-cancer-center.png)
Principal Investigator: Wendy Stock
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Chicago, Illinois 60608
Principal Investigator: Pam G. Khosla
Phone: 773-257-5960
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45202
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45211
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45230
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)